Letrozole for low-grade ovarian cancer that uses hormones
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests whether letrozole, a hormone-blocking medicine, can help people with newly diagnosed low-grade serous ovarian cancer that has hormone receptor proteins (ER and/or PgR) after surgery. It compares outcomes to see if blocking estrogen can slow the cancer’s return or progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older with newly diagnosed low-grade serous ovarian (or fallopian tube or peritoneal) cancer
- Your tumor test shows at least 10% ER and/or PgR positive (this is checked by a central lab)
- You already had upfront surgery to remove as much tumor as possible, with stage III–IV disease
- You are post-menopausal and can take pills by mouth
- You can start the study within 60 days after your main surgery and your body is strong enough for treatment (blood tests and heart/blood health criteria)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral targeted drugs (avutometinib and defactinib) plus letrozole (a hormone therapy) in people with low-grade serous ovarian cancer who have not yet had any systemic treatment.
This trial tests whether abemaciclib with letrozole can slow or shrink certain rare ovarian cancers that have estrogen receptors. It may help people whose cancer has come back and can be measured on scans, with extra required tissue and blood tests.
This Phase 3 trial tests whether ongoing treatment with an aromatase inhibitor (a hormone-blocking medicine) after initial chemotherapy can help keep epithelial ovarian/fallopian tube/peritoneal cancer from coming back. It is only for certain tumor types that are hormone-receptor positive (ER+).
This trial tests if a lower dose of the hormone therapy drug letrozole can work as well as the standard dose for people with early-stage hormone receptor-positive breast cancer. The lower dose may cause fewer side effects while still helping to prevent the cancer from coming back.
This trial tests a combination of two oral targeted drugs for people with recurrent low-grade serous ovarian cancer. It aims to see if this therapy works better than standard hormone therapy or chemotherapy options.
This trial tests whether taking letrozole, a hormone-blocking pill, before surgery can help shrink estrogen-positive breast cancer. It is for women who have gone through menopause and have early-stage cancer that has spread to nearby lymph nodes.
Hear when a new Carcinoma, Ovarian Epithelial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.